ENDOCRINE-PARACRINE CELL-TYPES IN THE PROSTATE AND PROSTATIC ADENOCARCINOMA ARE POSTMITOTIC CELLS
ENDOCRINE-PARACRINE CELL-TYPES IN THE PROSTATE AND PROSTATIC ADENOCARCINOMA ARE POSTMITOTIC CELLS
复制标题
DOI：
10.1016/0046-8177(95)90033-0
复制
发表时间：
1995-02-01
期刊：
影响因子：
3.3
通讯作者：
REMBERGER, K
中科院分区：
文献类型：
--
作者：
BONKHOFF, H;STEIN, U;REMBERGER, K
神经内分泌（NE）分化经常发生在常见的前列腺恶性肿瘤中，具有潜在的预后和治疗意义。在最近的一项研究中，我们能够提供免疫组织化学证据，证明内分泌旁分泌细胞类型代表前列腺癌中雄激素不敏感的细胞群，并通过持续缺乏相关受体来证明。在这项研究中，我们研究了内分泌旁分泌细胞类型在正常、增生和肿瘤前列腺组织中的增殖活性。利用双标记技术检测内分泌标记物嗜铬粒蛋白A （chr A）和增殖相关的mb -1抗原，我们评估了前列腺和前列腺腺癌中内分泌旁分泌细胞类型的增殖状态，这些细胞类型表现出明显的NE分化。在这一系列的癌和非肿瘤组织中，增殖活动仅限于非内分泌细胞群，而以Chr A为特征的内分泌-旁分泌细胞类型始终缺乏mb -1免疫反应性。这可能表明前列腺内分泌旁分泌细胞类型在正常、增生和肿瘤前列腺生长过程中不参与细胞周期。基于目前的信息，内分泌表型可以被认为是雄激素不敏感的，有丝分裂后的前列腺和前列腺癌亚群。版权所有(C) 1995由W.B.桑德斯公司
Neuroendocrine (NE) differentiation frequently occurs in common prostatic malignancies and has potential prognostic and therapeutic implications. In a recent study we were able to provide immunohistochemical evidence that endocrine-paracrine cell types represent an androgen-insensitive cell population in prostate cancer, documented by the consistent lack of the pertinent receptor. In this study we investigated the proliferative activity of endocrine-paracrine cell types in normal, hyperplastic, and neoplastic prostate tissue. Using double-label techniques for the endocrine marker chromogranin A (chr A) and the proliferation-associated MIB-1 antigen, we evaluated the proliferative status of endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma showing marked NE differentiation. In this series of carcinomas and in nonneoplastic tissue the proliferative activities were exclusively restricted to nonendocrine cell populations, whereas endocrine-paracrine cell types characterized by Chr A consistently lack MIB-1 immunoreactivity. This may indicate that prostatic endocrine-paracrine cell types do not participate in the cell cycle during normal, hyperplastic, and neoplastic prostatic growth. Based on the present information, the endocrine phenotype can be considered to be an androgen-insensitive, postmitotic subpopulation in the prostate and prostate cancer. Copyright (C) 1995 by W.B. Saunders Company